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Abstract
Background: Botulinum neurotoxin (BoNT) is the most potent poison known to mankind.
Currently no antidote is available to rescue poisoned synapses. An effective medical
countermeasure strategy would require developing a drug that could rescue poisoned
neuromuscular synapses and include its efficient delivery specifically to poisoned presynaptic nerve
terminals. Here we report a drug delivery strategy that could directly deliver toxin inhibitors into
the intoxicated nerve terminal cytosol.
Results:  A targeted delivery vehicle was developed for intracellular transport of emerging
botulinum neurotoxin antagonists. The drug delivery vehicle consisted of the non-toxic
recombinant heavy chain of botulinum neurotoxin-A coupled to a 10-kDa amino dextran via the
heterobifunctional linker 3-(2-pyridylthio)-propionyl hydrazide. The heavy chain served to target
botulinum neurotoxin-sensitive cells and promote internalization of the complex, while the dextran
served as a platform to deliver model therapeutic molecules to the targeted neurons. Our results
indicated that the drug delivery vehicle entry into neurons was via BoNT-A receptor mediated
endocytosis. Once internalized into neurons, the drug carrier component separated from the drug
delivery vehicle in a fashion similar to the separation of the BoNT-A light chain from the holotoxin.
This drug delivery vehicle could be used to deliver BoNT-A antidotes into BoNT-A intoxicated
cultured mouse spinal cord cells.
Conclusion: An effective BoNT-based drug delivery vehicle can be used to directly deliver toxin
inhibitors into intoxicated nerve terminal cytosol. This approach can potentially be utilized for
targeted drug delivery to treat other neuronal and neuromuscular disorders. This report also
provides new knowledge of endocytosis and exocytosis as well as of BoNT trafficking.
Background
Botulinum neurotoxins (BoNTs) are produced by the
anaerobic Clostridium botulinum species of bacteria and are
the cause of botulism, a life-threatening neuroparalytic
disease. They are extremely potent food poisons, with a
mouse LD50 of 0.1 ng/kg for type A [1,2]. Aerosol exposure
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of BoNTs does not occur naturally, but could be
attempted by bioterrorists to achieve a widespread effect.
It has been estimated that a single gram of crystalline
toxin, evenly dispersed and inhaled, could kill more than
one million people [2].
BoNTs are large proteins with a molecular weight of 150
kDa. They are produced as a complex containing the neu-
rotoxins and associated proteins [3]. They are synthesized
as inactive single chain protoxins and are activated by pro-
tease nicking to form a dichain molecule (a 50 kDa light
chain (LC) and a 100 kDa heavy chain (HC)) linked
through a disulfide bond [4]. The HC is responsible for
binding to the target nerve cells (through its C-terminus)
and translocating the LC into the cell cytoplasm (through
its N-terminus) [5,6].
Inside the neuronal cytosol, the LC acts as a Zn2+-
endopeptidase against specific intracellular protein targets
present either on the plasma membrane or on the synap-
tic vesicle, and inhibits neurotransmitter release by disa-
bling the exocytotic docking/fusion machinery [5,6].
BoNTs catalyze proteolysis of specific proteins of the sol-
uble NSF attachment protein receptor (SNARE) complex
that have been implicated in the exocytotic machinery
[5,7]. BoNT/A,/C, and /E cleave a 25 kDa synaptosomal
associated protein (SNAP-25).
Current therapy for botulism involves respiratory sup-
portive care and the administration of antitoxin. The anti-
toxin could be the currently available equine BoNT
antibodies or potentially more effective recombinant
multivalent antibodies. However, only a few antitoxins,
which must be administered before toxins reach the nerve
cells, are available. Thus, the therapeutic window for
using an antitoxin is short. Once the syndrome is devel-
oped, the antitoxin is less effective since it cannot pene-
trate the nerve cell to neutralize the toxin. The flaccid
muscle paralysis caused by BoNT/A lasts for several
months [8]. Therefore, patients who have already devel-
oped the syndrome must be put under respiratory inten-
sive care during paralysis [1,2,9]. Should a bioterrorist
attack occur, public health crisis could arise due to the lack
of effective antidotes against botulism, especially in the
absence of reliable presymptomatic diagnostics.
For relief from BoNT-mediated paralysis, it is important to
rescue the poisoned nerve cells through restoration of the
neurotransmitter release process. While drugs have been
designed to block the BoNT endopeptidase activity, which
is believed to be responsible for the inhibition of neuro-
transmitter release, delivery of the drugs specifically to the
poisoned nerve terminals remains a major hurdle. Thera-
peutic targeting is important for two main reasons: (a)
delivering an effective high concentration of the therapeu-
tic compound to the site of toxicity, i.e., nerve terminals
for botulism, and (b) minimizing systemic toxicity, if any,
due to treatment compounds. At present, some examples
of the proposed pharmacological antidotes for BoNT poi-
soning are a protease inhibitor, a phospholipase A2 activa-
tor or a modulator of intracellular free Ca2+ concentration.
Since all of these parameters are involved in normal body
functions, a systemic therapeutic approach is inadvisable
due to potential toxicity concerns.
Therefore, we developed a drug delivery vehicle (DDV)
comprising the non-toxic recombinant heavy chain of
BoNT-A coupled to a 10-kDa amino dextran via the heter-
obifunctional linker 3-(2-pyridylthio)-propionyl
hydrazide. The heavy chain served to target botulinum
neurotoxin-sensitive cells and promote internalization of
the complex, while the dextran served as a platform to
deliver model therapeutic molecules to the targeted cells.
Results
Structure of DDV
Initially we designed a DDV utilizing the recombinant
BoNT/A heavy chain (rHC), which is known to specifi-
cally bind to the presynaptic nerve terminals and be inter-
nalized via endocytosis. The DDV construct was a
modification of that developed by Goodnough et al. [10]
consisting of a targeting molecule, Cy3 labeled purified
(from the holotoxin) HC linked by a disulfide bond to a
drug simulant, which was Oregon green 488 (OG488)
labeled 10 kDa dextran (Fig. 1). The DDV structure was
used for further experiments. To our knowledge, this is the
first experimental demonstration of a prospective thera-
peutic approach to treat botulism in a relevant peripheral
neuronal model combined with a feasible targeted drug
delivery technology.
rHC was a safe DDV component for delivery of BoNT 
antidotes
To exclude any possible toxicity of the rHC component in
our DDV construct, we compared the inhibition of 80
mM K+ stimulated [3H]glycine release due to increasing
concentrations of rHC or native BoNT/A holotoxin by the
assay described in Methods. In these experiments, the
results obtained using the particular batch of toxin
showed that BoNT/A was quite toxic, as expected, with an
IC50 (toxin concentration to cause 50% inhibition of neu-
roexocytosis in untreated control cells) of approximately
<1 pM and a total inhibition at ~0.1 nM. However, a
much higher concentration of rHC, up to 200 nM, did not
show any inhibition of [3H]glycine release under the same
assay conditions (Fig. 2).
DDV entry into neurons via BoNT/A receptor mediated 
endocytosis
The experimental design was to mimic a therapeutic
application of the DDV strategy to treat individuals poi-
soned with BoNT/A and exhibiting clinical symptoms ofBMC Pharmacology 2009, 9:12 http://www.biomedcentral.com/1471-2210/9/12
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botulism. Since the targeted DDV approach is based on
the premise of a selective entry of DDV into presynaptic
nerve terminals via BoNT/A receptor mediated endocyto-
sis, we demonstrated by competition experiments that the
uptake of the DDV-Mas-7 was via BoNT/A receptors. In
these experiments, 3-week old spinal cord cultures were
exposed for 16 hours to DDV (200 nM) alone or to DDV
plus a 1-, 3-, or 10-fold excess of unlabeled rHC (Fig. 3,
A1-A4) or BoNT/A holotoxin (Fig. 3, B1-B4) added to cul-
tures simultaneously. As seen in Fig. 3, in the absence of
rHC or BoNT/A, DDV uptake and dextran separation were
as expected; however, a 10-fold excess of rHC or BoNT/A
holotoxin completely blocked the uptake of DDV. These
results suggested that DDV entry into neurons occurred by
the same route as used by BoNT/A.
Drug carrier could be separated from DDV in a fashion 
BoNT/A LC dissociates from the HC in the holotoxin
To determine the efficacy of delivering the therapeutic
compound, we studied the separation of the drug carrier
from DDV. Confocal microscopy was used to detect the
separation of the DDV components. Spinal cord neurons
were treated for 16 hours with 200 nM labeled DDV at
37°C. The staining pattern of unseparated DDV was
orange (red plus green labeling) and punctate (Fig. 4, D1,
D2 and 4, D3). The punctate nature of the staining sug-
gested clustering of DDV in vesicles. The images shown in
Fig. 4 highlight the presence of released drug carrier
(green) in the particles present in the nerve terminal
cytosol. Inclusion of endosome staining (blue) indicated
that the DDV was intra-endosomal (Purple, which was red
plus blue staining, Fig. 4, E1, E2 and 4, E3) as expected for
material transported by BoNT HC. It indicated that the
separation of the drug carrier from DDV was in a fashion
similar to the dissociation of BoNT/A LC from the HC in
the holotoxin.
Separation of drug carrier from DDV was neuronal 
maturation-dependent
Different stages of spinal cell culture growth were used to
evaluate the efficacy of separation of drug carrier from
DDV. Confocal image analysis revealed that about 20, 32
and 40% of the drug carrier component separated from
DDV and diffused into the cytosol from endosomes in 1,
2 and 3 weeks culture, respectively (Fig. 4, D1, D2 and 4,
D3; table 1). These results indicated that the separation of
the drug carrier from DDV is neuronal maturation-
dependent. Furthermore, the separations of DDV compo-
nents occur in a time-dependent manner [see additional
file 1, Fig S1].
Schematic representation of the DDV for transport of BoNT/A antagonists Figure 1
Schematic representation of the DDV for transport of BoNT/A antagonists. The schematic representation ofthe 
DDV construct without drug. The PDPH linker is bound to one of four possible cysteine (C) sulfhydryl groups on the BoNT/A 
rHC. It is attached to C454, which normally participates in the disulfide linkage with the LC. Cy3 and Oregon green 488 are 
bound to O-amino groups of lysine in the rHC and dextran, respectively. The dextran is conjugated to the rHC by a C-N bond 
in one of the glucose residues. In a functional DDV, multiple drug molecules may be attached to dextran carrier.
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DEXTRAN-10
BoNT/A rHC
Cy3
HN
O
S
S
C454
Oregon Green 488BMC Pharmacology 2009, 9:12 http://www.biomedcentral.com/1471-2210/9/12
Page 4 of 9
(page number not for citation purposes)
The processes of exocytosis and endocytosis are not tightly 
coupled
It is possible that in neurons, the processes of exocytosis
and endocytosis are tightly coupled, i.e., interruption of
exocytosis, as in BoNT/A poisoning, might halt endocyto-
sis as well. If true, the DDV approach as presented here
would not be a feasible drug delivery system in BoNT poi-
soned neurons because the uptake of DDV, via endocyto-
sis, could be blocked as a sequel of exocytosis blockade by
BoNT. To discount this possibility, we demonstrated
uptake of labeled DDV (red fluorescence), of which Ore-
gon green 488 was omitted and and only Cy3 was used, in
spinal cord neurons previously exposed to a high concen-
tration (1 nM) of Alexa 488-labeled BoNT-A (green flores-
cence); 1 nM BoNT-A had completely blocked K+-
stimulated [3H]glycine release. To examine DDV-Mas-7
uptake in these cells, the cells were washed once using
warm culture medium and reincubated at 37°C with 100
nM DDV for 16 hours. Confocal microscopy results indi-
cated that both BoNT/A and DDV were taken up in the
same cell pool, but localized in separate population of
endosomes (Fig. 5), demonstrating internalization of
DDV via endocytosis into BoNT/A poisoned neurons.
This suggested that the exocytosis and endocytosis are not
tightly coupled in BoNT/A poisoned neurons.
Discussion
Primary cultures of spinal cord represent a convenient and
sensitive system to study mechanisms of neurotransmit-
ters release [11,12]. Internalized neurotransmitters by spi-
nal cord neurons in culture were released quantitatively in
response to depolarization and Ca2+. This release is inhib-
ited by tetanus toxin and botulinum neurotoxins in a con-
centration- and time-dependent manner [13-17].
Therefore, this system serves as a suitable model to exam-
ine the efficacy of prospective BoNT countermeasures.
Sheridan and Adler indicated that the evoked release of
neurotransmitters, notably glycine, in this system was
time-dependently increased [18]. In our studies, there was
a pronounced time-dependent increase of the drug carrier
separation from DDV, which paralleled an enhancement
of transmitter release.
rHC was a safe DDV component to delivery antidotes Figure 2
rHC was a safe DDV component to delivery antidotes. Primary cultures of mouse spinal cord were exposed to BoNT/
A (n) or rHC (m) respectively in indicated concentrations for 16 hrs. Potassium-evoked glycine release was measured. Results 
expressed as percentage glycine release compared with untreated control. Data points are the mean (± SD) of three separate 
experiments each determined in triplicate.BMC Pharmacology 2009, 9:12 http://www.biomedcentral.com/1471-2210/9/12
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We postulate that the ability of drug carrier to separate
from DDV in our spinal cord cell culture model is depend-
ent upon neuronal maturation at increasing age of the cul-
tures. Regarding DDV uptake and processing in neurons,
the results in Fig 4 clearly demonstrated the following
facts. The red (Cy3-rHC) (A1-A3) and the blue (Alexa 633-
endosome) (C1-C3) fluorescence signals were strongly
present in neurons at any stage of development, however,
were always in a distinct punctate localization. Moreover,
the red and the blue signals were always co-localized (E1-
E3) and the red signals never diffused into the cytosol.
These observations indicated that the DDV was readily
internalized into neurons apparently via endocytosis and
the rHC component remained in the endosomes as gener-
ally believed to be the case in BoNT endocytosis and traf-
ficking phenomena. The HC remains localized in the
endosome and not released into the cytosol. These micro-
graphs exhibit both punctuate and diffused distribution
of signals with the level of diffusion apparently increasing
with increased age of cultures. This observation may be
explained as follows: in mature neurons, the DDV is taken
up into endosomes, the dextran component separates
from the rHC and then gets released into the cytosol. This
explanation is supported by our results presented in the
micrographs showing the overlays of red and green fluo-
rescence (D1-D3) and those of green and blue fluores-
cence (F1-F3). In D1-D3, overlap of red and green
generated orange indicating intact DDV; the released
OG488-dextran was green. It should be noted that the
orange was punctate suggesting endosomal localization,
whereas the green was diffuse suggesting the release of
OG488-dextran component of the DDV into the cytosol,
which was enhanced with increasing age of cultures.
Using the images in D1-D3, we calculated the separation
and release rates of OG488-dextran from the DDV by uti-
lizing the Bio-Rad AutoDeblur and AutoVisualize soft-
ware to quantitate fluorescence intensity. The separation/
release rates were expressed as 100% (total in images)
DDV entry into neurons via BoNT/A receptor mediated endocytosis Figure 3
DDV entry into neurons via BoNT/A receptor mediated endocytosis. Images in rows A and B were obtained from 
triplicate cultures exposed for 16 h under the following conditions: (A1) DDV (200 nM) in the absence of rHC; (A2) DDV (200 
nM) and rHC (200 nM); (A3) DDV (200 nM) and rHC (600 nM); and (A4) DDV (200 nM) and rHC (2 μM); (B1) DDV (200 nM) 
in the absence of BoNT/A; (B2) DDV (200 nM) and BoNT/A (200 nM); (B3) DDV (200 nM) and BoNT/A (600 nM); and (B4) 
DDV (200 nM) and BoNT/A (2 μM). DDV and rHC or BoNT/A were added simultaneously. Note the progressive reductions 
in fluorescence with increasing concentrations of BoNT/A or rHC. Micrographs were obtained on a Bio-Rad 2000 laser micro-
scope confocal microscope using a 100× oil immersion objective. The fluorescence colors of labelled molecules are: red-rHC; 
green-OG488-dextran.
A1  A2  A3                             A4
B1  B2  B3                             B4BMC Pharmacology 2009, 9:12 http://www.biomedcentral.com/1471-2210/9/12
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Separation of the drug carrier molecule in DDV and its translocation into neuronal cytosol is cell maturation dependent Figure 4
Separation of the drug carrier molecule in DDV and its translocation into neuronal cytosol is cell maturation 
dependent. The figure shows fluorescent images of mouse spinal cord neurons. Cells at different stages of culture were incu-
bated for 16 h with 200 nM solutions of fluorescently labeled DDV, and then labeled with anti-endosome antibody as described 
under methods. Confocal images shown are as follows: A1-A3, red-rHC; B1-B3, green-OG488-dextran; C1-C3, bright blue-
Alexa 633-endosomes; D1-D3, overlay of red and green showing either co-localization (orange) or separation of rHC and dex-
tran; E1-E3, overlay of red and blue showing either the localization (magenta) of rHC in the endosomes or its release into the 
cytosol, if any; F1-F3, overlay of green and blue showing either localization (light blue or greenish blue) of dextran in the endo-
somes or its release into the cytosol. The numerical suffixes as in A1, A2 and A3 indicate culture age, i.e., one- (top panels), 
two- (middle panels) or three-week (bottom panels) old. The results clearly demonstrated that the rHC component of the 
DDV remained localized in the endosomes, while the OG488-dextran separated from the DDV and migrated into the cytosol.
A1      B1              C1
D1      E1              F1
A2      B2              C2
D2      E2              F2
A3      B3              C3
D3      E3              F3BMC Pharmacology 2009, 9:12 http://www.biomedcentral.com/1471-2210/9/12
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minus percentage of co-localization rate (Table 1). In F1-
F3, overlap of bright blue and green generated light or
greenish blue indicating OG488-dextran remaining in the
endosomes; the released OG-dextran was green. On exam-
ining the D1-D3, E1-E3 and F1-F3 micrographs, it is inter-
esting to note that intact DDV (D1-D3), rHC (E1-E3) and
unreleased dextran all seem to be localized in the same
endosomal pool; this provides additional support to our
proposed mechanism of DDV uptake and processing. Rel-
evant to this proposition, most significant was our dem-
onstration that in neurons, the DDV function that
required an efficient endocytotic mechanism was devel-
opmentally regulated, i.e., neuronal maturation-depend-
ent. Moreover, our results showed that the efficiency in
neuroexocytosis was also a function of mature neurons.
To demonstrate the feasibility of delivering a therapeutic
compound via the DDV, we examined the separation of
the prototype drug carrier dextran from DDV. The results
indicated that the drug carrier components were satisfac-
torily separated from DDV and diffused into cytosol. As
described in the results section, the targeting component
of the DDV, i.e., rHC was nontoxic. Therefore, the DDV
approach presented here may be a physiologically com-
patible and a feasible targeted drug delivery method to
counteract botulism.
Although it was believed to be the case, our results pro-
vided the first experimental evidence that the HC of
BoNT/A upon internalization into neurons remains local-
ized in the endosomes and thus, does not participate in
the cytosolic mechanism of BoNT/A toxicity. Very mean-
ingful was the fact that BoNT/A poisoned neurons, which
were totally incapable of stimulated exocytosis, could still
incorporate the HC via endocytosis. This was apparently
due to new or spare receptors available for HC molecule
binding on the plasma membrane. Furthermore, the exo-
cytosis and endocytosis phenomena in neurons may not
necessarily be coupled tightly. Neale et al. also reported
that BoNT/A blocked synaptic vesicle exocytosis but not
endocytosis at nerve terminal [20].
In conclusion, this report provides new knowledge of
endocytosis and exocytosis, as well as of BoNT trafficking
and action. Notably, application of this DDV approach to
antagonize botulism is not necessarily limited to the neu-
ronal targeting of BoNT as shown here, but also should be
useful for delivery of other prospective antidotes, such as
protease inhibitors to protect the vesicle fusion proteins as
applicable. Finally, the success in the DDV strategy against
botulism shown here may open new avenues in develop-
ing technologies to treat other neurological disorders that
require a targeted delivery of therapeutics to affected neu-
rons or tissues. Before the actual studies are conducted, we
can only speculate on a possible route of administration
of the DDV as a therapeutic in a patient. Oral or inhala-
tion routes are inadvisable. The oral administration may
result in DDV degradation in the gastrointestinal system.
The inhalation administration may result in a slower DDV
absorption and may also require a high DDV concentra-
tion, which could possibly trigger a cell-mediated
immune response. Based on these considerations, we pro-
pose the intravenous route which should rapidly achieve
a high DDV level in the circulation for an effective drug
delivery into BoNT poisoned nerve terminals.
Conclusion
An effective botulinum neurotoxin-based drug delivery
vehicle can be used to directly deliver toxin inhibitors into
the intoxicated nerve terminal cytosol. The concept may
possibly be utilized for drug delivery for other neuronal
and neuromuscular disorders. Besides a BoNT therapeutic
approach, this report also provides new fundamental
knowledge of endocytosis and exocytosis as well as of
BoNT trafficking in neurons.
Methods
Construct a model drug conjugated drug delivery vehicle
We designed a DDV utilizing recombinant BoNT/A heavy
chain (rHC), which is known to specifically bind to the
presynaptic nerve terminals and be internalized via endo-
cytosis. The DDV construct was a modification of that
developed by Goodnough et al., [10]. The DDV consisted
of a targeting molecule, Cy3 labeled rHC linked by a
disulfide bond at Cys454 of rHC to a drug simulant, Ore-
gon green 488 (OG488) labeled 10 kDa dextran (Fig. 1).
The DDV construct was soluble in aqueous medium and
was stable under our experimental conditions, i.e., at
37°C.
Spinal cord cultures
Timed pregnant C57BL/6NCR mice were obtained from
the Frederick Cancer Research and Development Center
(Frederick, MD). Research was conducted in compliance
with the Animal Welfare Act and other federal statutes and
regulations relating to animals and experiments involving
animals and adheres to principles stated in the Guide for
the Care and Use of Laboratory Animals, NRC Publication,
1996 edition. Spinal cords were removed from fetal mice
at gestation day 13. Cells were dissociated with trypsin
and plated in collagen-coated 4 well coverslips or 35 mm
diameter 6-well culture plates at a density of 105 cells/cm2.
Cells were grown in Eagle's Minimum Essential Medium
Table 1: The drug carrier separation from DDV is cell 
maturation-dependent
Cell growth period 1 week 2 weeks 3 weeks
Drug carrier separation rate (%) 20 ± 3 32 ± 5 40 ± 4BMC Pharmacology 2009, 9:12 http://www.biomedcentral.com/1471-2210/9/12
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with 5% heat-inactivated horse serum and a nutrient sup-
plement (N3) at 37°C in 90% air/10% CO2. Cell cultures
were treated with 54 mM 5-fluoro-2-deoxyuridine and
140 mM uridine from day 5-9 after plating to inhibit glial
proliferation. Cultures were fed 1-2 times per week and
were used for experiments at 1 to 3 weeks after plating.
3[H]glycine release assay
3 [H]glycine release was determined by a modification of
the method described by Williamson et al. [19]. Spinal
cord cells were incubated at 37°C for 30 min in HEPES-
buffered saline (HBS) containing 2 mCi/ml 3 [H]glycine.
The cells were washed briefly with Ca2+-free HBS and
incubated sequentially for 7 min in each of the following
modified HBS solutions: 5 mM KCl/0 mM Ca2+, 80 mM
KCl/2 mM Ca2+ and 5 mM KCl/0 mM Ca2+. Each incuba-
tion solution was collected, and the radioactivity was
determined by scintillation counting.
Uptake of DDV by spinal cord neurons and release of 
dextran
Cells were exposed to DDV, Cy3-labeled rHC, or Oregon
green 488-labeled dextran in growth medium for 16 h at
a concentration of 200 nM at 37°C. Cells were subse-
quently washed three times with growth medium and
fixed overnight using 2% paraformaldehyde. The cover-
slips containing fixed cells were mounted between a glass
slide and glass coverslip and viewed on a Bio-Rad 2000
laser confocal microscope. Oregon green 488 was excited
at 488 nm and read through a 515-nm cutoff filter. Cy3
was excited at 543 nm and read through a 565-nm cutoff
filter. To minimize photobleaching, Slowfade Light was
added to the mounting medium. Micrographs were
obtained using a Bio-Rad laser confocal microscope with
a 100× oil immersion objective. Images were collected
with Bio-Rad software. Co-localization of rHC and dex-
tran and separation rates of dextran from DDV were then
calculated by utilizing the Bio-Rad AutoDeblur and Auto-
Visualize software to quantitate fluorescence intensity.
Separation rates were expressed as % total minus % co-
localization.
Determination of rHC localization
Experimental procedures were similar to those described
above under "Uptake of DDV by spinal cord neurons and
release of dextran", except that after fixing with 2% para-
formaldehyde, cells were subsequently washed three
times with D-PBS and permeabilized with 0.2% TritonX-
100 for 10 min in room temperature (RT). Cells were
blocked with 4% BSA in D-PBS at 4°C for 1 h and subse-
quently incubated with goat anti-EEA1 antibody at RT for
1 hr. After wash five times with D-PBS, cells were incu-
bated with a secondary antibody (donkey anti goat-Alexa
633) at RT for 0.5 h. Cells were subsequently washed three
times with D-PBS. The coverslips containing fixed cells
were mounted between a glass slide and glass coverslip
and viewed on a Bio-Rad 2000 laser confocal microscope.
Excition and emmission for Cy3 and OG-488 were as
Exocytosis and endocytosis are not tightly coupled in BoNT/A poisoned neurons Figure 5
Exocytosis and endocytosis are not tightly coupled in BoNT/A poisoned neurons. (a) BoNT/A was labeled with 
Alexa 488 (green fluorescence). Three week-old cultured mouse spinal cord neurons were incubated with a culture medium 
containing 1 nM of Alexa 488-BoNT/A for 8 hours at 37°C. Excess Alexa 488-BoNT/A was removed by washings 3 times with 
fresh culture medium. The cells were incubated with fresh medium for 1 hour and then incubated in medium containing 100 
nM Cy3 (red fluorescence) labeled DDV for 16 hours (b). (c) Overlay of red and green showing both BoNT/A (green) and 
DDV (red) were taken up in the same cell pool, but localized in separate population of endosomes. Fluorescent images were 
analyzed by Bio-Rad 2000 laser confocol microscope. Alexa 488 was excited at 488 nm line of an argon laser and detected with 
a 530-nm cutoff filter; Cy3 was excited at 543 nm line of an argon laser and detected with a 565-nm cutoff filter.
Overlay of two images Cy3-DDV-mas7 Alexa488-BoNT/ABMC Pharmacology 2009, 9:12 http://www.biomedcentral.com/1471-2210/9/12
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stated above. Alexa 633 was excited at 632 nm and
detected with a 649 nm cutoff filter. Micrographs were
obtained using a Bio-Rad laser confocal microscope with
a 100× oil immersion objective.
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Fig. S1. Fluorescent images of mouse spinal cord neurons demonstrat-
ing that the separations of DDV components occur in a time-depend-
ent manner. Three weeks old cultured cells were incubated for 1 h (A), 
12 h (B) and 24 h (C) with 200 nM solutions of fluorescently labeled 
DDV. Confocal images shown are as follows: A, red-rHC that fluores-
cence elicited at an excitation wavelength of 543 nm; B, green-OG488-
dextran that fluorescence elicited at an excitation wavelength of 488 nm. 
The micrographs represent overlays of the two images, red and green. Sep-
aration of dextran from rHC is observed at 12 h or earlier.
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